LIMA, Peru, June 13, 2016 -- Camposol Holding Ltd. announces that Mrs. Maria Elena Olmos leaves the Investor Relations Officer position in Camposol Holding Ltd. in order to become CFO of the D&C Group Family Office. Mr. Jossue Yesquen has been promoted to Head of Investors Relations after finishing his transition period.
Mrs. Olmos holds a Bachelor's Degree of Science in Business Administration and Economics from University of South Carolina Spartanburg, USA and is currently enrolled in the EMBA Program at Kellogg Northwestern University. She has over 10 years of experience, including positions in the public and private sector in companies and institutions such as Bank of America, Ministry of Foreign Trade and Tourism, Copeinca and Camposol. She began working with D&C Group in 2007 and ever since has participated in all Debt Capital Markets, Equity Capital Markets, and syndicated transactions.
"Maria Elena with her dedication, professionalism and a unique strive for service, has helped to position Camposol and D&C Group in the financial markets, while developing a strong bond with investors and financial institutions, which were key elements to successfully execute important ECM and DCM transactions, including the latest refinancing of Camposol's secured notes due 2017. We would like to thank Maria Elena for all she has accomplished for Camposol and D&C Group, and want to wish her the best in her new role in our Family Office," said Samuel Dyer Coriat, Chairman of the Board.
For further information, please contact:
CEO, Manuel Salazar Diez Canseco
[email protected]
CFO, Maria Cristina Couturier
[email protected]
Head of Investor Relations, Jossue Yesquen
[email protected]
About CAMPOSOL
CAMPOSOL is the leading agro industrial company in Peru, the first producer of avocados and soon the first producer of blueberries in the world. It is involved in the harvest, processing and marketing of high quality agricultural products such as avocados, asparagus, blueberries, grapes, mangoes, tangerines and shrimp; which are exported to Europe, the United States of America and Asia.
CAMPOSOL is a vertically integrated company located in Peru, offering fresh and frozen products. It is the third largest private employer of the country, with more than 13 thousand workers in high season, and is committed to support sustainable development through social responsibility policies and projects aimed to increase the shared-value for all of its stakeholders.
CAMPOSOL was the first Peruvian agro industrial company to present annual audited sustainability reports. CAMPOSOL has achieved the following international certifications: BSCI, Global Gap, IFS, HACCP and BRC among others.
To learn more about CAMPOSOL please visit: www.camposol.com.pe
HUG#2020377


Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Italy Fines Apple €98.6 Million Over App Store Dominance
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



